Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
Status:
Terminated
Trial end date:
2023-01-20
Target enrollment:
Participant gender:
Summary
Purpose of Study This exploratory clinical study will investigate FMISO (fluoromisonidazole)
in patients with (1) newly diagnosed primary malignant brain tumors (WHO [World Health
Organization] Grade III or IV glial-based tumors) who have not had a complete surgical
resection and by contrast MRI (Magnetic resonance imaging) have residual tumor > 1.0 cm in
diameter and will be receiving radiotherapy or (2) newly diagnosed brain metastasis (> 1.0 cm
in diameter who will be receiving radiotherapy. The ability to accurately assess tumor
hypoxia and accurately determine the amount/degree of tumor hypoxia could potentially change
patient management once validated as tumor hypoxia is known to be associated with a poor
prognosis [Eyler 2008].